An­no­vis Bio claims wins in Alzheimer's and Parkin­son's, shares sky­rock­et; FDA de­lays de­ci­sion for Omeros' nar­so­plimab

A Berwyn, PA-based biotech is claim­ing a huge win in both Alzheimer’s and Parkin­son’s dis­eases, and it’s send­ing their shares sky­rock­et­ing.

An­no­vis Bio re­port­ed re­sults from a small co­hort of a Phase II study, con­tain­ing 14 Alzheimer’s pa­tients and 14 Parkin­son’s pa­tients in a tri­al for a pro­gram called AN­VS401. Mea­sur­ing cog­ni­tive im­prove­ment with an as­sess­ment scale known as ADAS-Cog11, An­no­vis said pa­tients’ scores im­proved by about 30% over their base­lines af­ter 25 days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER